{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T12:16:46Z","timestamp":1788265006653,"version":"build-2803163510"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["2R01CA102363"],"award-info":[{"award-number":["2R01CA102363"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015194","name":"Feist-Weiller Cancer Center","doi-asserted-by":"publisher","award":["149741524A"],"award-info":[{"award-number":["149741524A"]}],"id":[{"id":"10.13039\/100015194","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.neo.2026.101350","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T15:16:35Z","timestamp":1786202195000},"page":"101350","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["mTOR inhibition augments antitumor immune effector response by reprogramming the TP53-mutant, immune-cold HNSCC tumor microenvironment"],"prefix":"10.1016","volume":"80","author":[{"given":"Priyatosh","family":"Nath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok","family":"Khandelwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Moore-Medlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6998-1658","authenticated-orcid":false,"given":"Srivatsa Surya","family":"Vasudevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1312-6764","authenticated-orcid":false,"given":"Victor Albornoz","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0673-9506","authenticated-orcid":false,"given":"Omar E.","family":"Franco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5150-4482","authenticated-orcid":false,"given":"J. Silvio","family":"Gutkind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7386-318X","authenticated-orcid":false,"given":"Cherie-Ann O.","family":"Nathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.neo.2026.101350_bib0001","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41572-020-00224-3","article-title":"Head and neck squamous cell carcinoma","volume":"6","author":"Johnson","year":"2020","journal-title":"Nat. Rev. Dis. Primers."},{"issue":"3","key":"10.1016\/j.neo.2026.101350_bib0002","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"12","key":"10.1016\/j.neo.2026.101350_bib0003","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1002\/jcb.25592","article-title":"TP53 Mutations in head and neck squamous cell carcinoma and their impact on disease progression and treatment response","volume":"117","author":"Zhou","year":"2016","journal-title":"J. Cell Biochem."},{"issue":"4","key":"10.1016\/j.neo.2026.101350_bib0004","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/mc.23385","article-title":"TP53 mutations in head and neck cancer","volume":"61","author":"Nathan","year":"2022","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.neo.2026.101350_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102905","article-title":"TP53 mutational landscape of metastatic head and neck cancer reveals patterns of mutation selection","volume":"58","author":"Klinakis","year":"2020","journal-title":"EBioMedicine"},{"issue":"8","key":"10.1016\/j.neo.2026.101350_bib0006","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/s41419-019-1769-9","article-title":"Clinical update on head and neck cancer: molecular biology and ongoing challenges","volume":"10","author":"Alsahafi","year":"2019","journal-title":"Cell Death. Dis."},{"key":"10.1016\/j.neo.2026.101350_bib0007","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/nature14129","article-title":"Comprehensive genomic characterization of head and neck squamous cell carcinomas","volume":"517","author":"Lawrence","year":"2015","journal-title":"Nature"},{"issue":"6381","key":"10.1016\/j.neo.2026.101350_bib0008","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/358015a0","article-title":"Cancer. p53, guardian of the genome","volume":"358","author":"Lane","year":"1992","journal-title":"Nature"},{"issue":"6810","key":"10.1016\/j.neo.2026.101350_bib0009","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/35042675","article-title":"Surfing the p53 network","volume":"408","author":"Vogelstein","year":"2000","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.neo.2026.101350_bib0010","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.3390\/cancers16173069","article-title":"TP53 mutation-mediated immune evasion in cancer: mechanisms and therapeutic implications","volume":"16","author":"Wang","year":"2024","journal-title":"Cancers. (Basel)"},{"issue":"1","key":"10.1016\/j.neo.2026.101350_bib0011","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11033-023-09097-7","article-title":"TP53 to mediate immune escape in tumor microenvironment: an overview of the research progress","volume":"51","author":"Zhu","year":"2024","journal-title":"Mol. Biol. Rep."},{"issue":"1","key":"10.1016\/j.neo.2026.101350_bib0012","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/s41467-018-03224-w","article-title":"Mutant p53 cancers reprogram macrophages to tumor supporting macrophages via exosomal miR-1246","volume":"9","author":"Cooks","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.neo.2026.101350_bib0013","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1038\/ncomms3359","article-title":"53 increases MHC class I expression by upregulating the endoplasmic reticulum aminopeptidase ERAP1","volume":"4","author":"Wang","year":"2013","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.neo.2026.101350_bib0014","doi-asserted-by":"crossref","first-page":"djv303","DOI":"10.1093\/jnci\/djv303","article-title":"PDL1 Regulation by p53 via miR-34","volume":"108","author":"Cortez","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"issue":"7","key":"10.1016\/j.neo.2026.101350_bib0015","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1158\/2159-8290.CD-13-0103","article-title":"Frequent mutation of the PI3K pathway in head and neck cancer defines predictive biomarkers","volume":"3","author":"Lui","year":"2013","journal-title":"Cancer Discov."},{"issue":"5","key":"10.1016\/j.neo.2026.101350_bib0016","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.celrep.2018.10.007","article-title":"Genomic and transcriptomic characterization links cell lines with aggressive head and neck cancers","volume":"25","author":"Cheng","year":"2018","journal-title":"Cell Rep."},{"issue":"7","key":"10.1016\/j.neo.2026.101350_bib0017","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.molonc.2016.04.001","article-title":"Mutant p53 proteins counteract autophagic mechanism sensitizing cancer cells to mTOR inhibition","volume":"10","author":"Cordani","year":"2016","journal-title":"Mol. Oncol."},{"issue":"23","key":"10.1016\/j.neo.2026.101350_bib0018","doi-asserted-by":"crossref","first-page":"8204","DOI":"10.1073\/pnas.0502857102","article-title":"The coordinate regulation of the p53 and mTOR pathways in cells","volume":"102","author":"Feng","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.neo.2026.101350_bib0019","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.775507","article-title":"The cross talk between p53 and mTOR pathways in response to physiological and genotoxic stresses","volume":"9","author":"Cui","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"issue":"21","key":"10.1016\/j.neo.2026.101350_bib0020","doi-asserted-by":"crossref","first-page":"6555","DOI":"10.1158\/1078-0432.CCR-19-2002","article-title":"Targeting mTOR in head and neck cancer-response","volume":"25","author":"Gutkind","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.neo.2026.101350_bib0021","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/mc.23357","article-title":"Rapalogs induce non-apoptotic, autophagy-dependent cell death in HPV-negative TP53 mutant head and neck squamous cell carcinoma","volume":"61","author":"Alam","year":"2022","journal-title":"Mol. Carcinog."},{"key":"10.1016\/j.neo.2026.101350_bib0022","doi-asserted-by":"crossref","first-page":"85","DOI":"10.18632\/oncotarget.28355","article-title":"Everolimus downregulates STAT3\/HIF-1\u03b1\/VEGF pathway to inhibit angiogenesis and lymphangiogenesis in TP53 mutant head and neck squamous cell carcinoma (HNSCC)","volume":"14","author":"Alam","year":"2023","journal-title":"Oncotarget"},{"issue":"8_Suppl_1","key":"10.1016\/j.neo.2026.101350_bib0023","article-title":"mTOR inhibition augments antitumor T cell response by modulating the expression of immune regulatory molecules","volume":"85","author":"Nath","year":"2025","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.neo.2026.101350_bib0024","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1158\/2326-6066.CIR-15-0252","article-title":"Enhanced tumor control with combination mTOR and PD-L1 inhibition in syngeneic oral cavity cancers","volume":"4","author":"Moore","year":"2016","journal-title":"Cancer Immunol. Res."},{"issue":"3","key":"10.1016\/j.neo.2026.101350_bib0025","doi-asserted-by":"crossref","first-page":"755","DOI":"10.3390\/ijms20030755","article-title":"mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy","volume":"20","author":"Tian","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.neo.2026.101350_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112868","article-title":"mTOR inhibition reprograms cellular proteostasis by regulating eIF3D-mediated selective mRNA translation and promotes cell phenotype switching","volume":"42","author":"Shin","year":"2023","journal-title":"Cell Rep."},{"issue":"4","key":"10.1016\/j.neo.2026.101350_bib0027","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1365-2567.2009.03125.x","article-title":"mTOR: taking cues from the immune microenvironment","volume":"127","author":"Delgoffe","year":"2009","journal-title":"Immunology"},{"key":"10.1016\/j.neo.2026.101350_bib0028","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.774103","article-title":"mTOR-mediated regulation of immune responses in cancer and tumor microenvironment","volume":"12","author":"Mafi","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.neo.2026.101350_bib0029","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s42003-022-03675-4","article-title":"Mutant p53 drives an immune cold tumor immune microenvironment in oral squamous cell carcinoma","volume":"5","author":"Shi","year":"2022","journal-title":"Commun. Biol."},{"issue":"34","key":"10.1016\/j.neo.2026.101350_bib0030","doi-asserted-by":"crossref","first-page":"36400","DOI":"10.18632\/oncotarget.5063","article-title":"mTOR and MEK1\/2 inhibition differentially modulate tumor growth and the immune microenvironment in syngeneic models of oral cavity cancer","volume":"6","author":"Cash","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.neo.2026.101350_bib0031","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1054186","article-title":"Olive leaves extract alleviates inflammation and modifies the intrinsic apoptotic signal in the leukemic bone marrow","volume":"13","author":"Nath","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.neo.2026.101350_bib0032","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0022-1759(88)90042-7","article-title":"Automated fluorometric assay for T cell cytotoxicity","volume":"112","author":"Brenan","year":"1988","journal-title":"J. Immunol. Methods"},{"issue":"5","key":"10.1016\/j.neo.2026.101350_bib0033","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/cmi.2014.104","article-title":"PD-1 induction through TCR activation is partially regulated by endogenous TGF-\u03b2","volume":"12","author":"Rekik","year":"2015","journal-title":"Cell Mol. Immunol."},{"issue":"1","key":"10.1016\/j.neo.2026.101350_bib0034","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/1878-0261.13103","article-title":"PD-1-induced T cell exhaustion is controlled by a Drp1-dependent mechanism","volume":"16","author":"Simula","year":"2022","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.neo.2026.101350_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2022.155913","article-title":"Immunotherapeutic potential of ethanolic olive leaves extract (EOLE) and IL-28B combination therapy in ENU induced animal model of leukemia","volume":"156","author":"Nath","year":"2022","journal-title":"Cytokine"},{"issue":"73","key":"10.1016\/j.neo.2026.101350_bib0036","doi-asserted-by":"crossref","first-page":"eabq6509","DOI":"10.1126\/sciimmunol.abq6509","article-title":"CXCL9 and CXCL10 bring the heat to tumors","volume":"7","author":"Reschke","year":"2022","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.neo.2026.101350_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.113678","article-title":"IRF1 transcriptionally up-regulates CXCL10 which increases CD8+ T cells infiltration in colorectal cancer","volume":"144","author":"Li","year":"2025","journal-title":"Int. Immunopharmacol."},{"issue":"5","key":"10.1016\/j.neo.2026.101350_bib0038","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.3390\/ijms22052719","article-title":"The role of tumor necrosis factor alpha (TNF-\u03b1) in autoimmune disease and current TNF-\u03b1 inhibitors in therapeutics","volume":"22","author":"Jang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"9","key":"10.1016\/j.neo.2026.101350_bib0039","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.3390\/biom11091355","article-title":"TNF-\u03b1 increases IP-10 expression in MCF-7 breast cancer cells via activation of the JNK\/c-Jun pathways","volume":"11","author":"Kochumon","year":"2021","journal-title":"Biomolecules"},{"issue":"28","key":"10.1016\/j.neo.2026.101350_bib0040","doi-asserted-by":"crossref","first-page":"20534","DOI":"10.1074\/jbc.M611782200","article-title":"Hypoxia-inducible factor 1alpha is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif","volume":"282","author":"Land","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"17","key":"10.1016\/j.neo.2026.101350_bib0041","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1038\/onc.2014.164","article-title":"mTORC1 drives HIF-1\u03b1 and VEGF-A signalling via multiple mechanisms involving 4E-BP1, S6K1 and STAT3","volume":"34","author":"Dodd","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.neo.2026.101350_bib0042","first-page":"362","article-title":"The mTOR pathway in the control of protein synthesis","volume":"21","author":"Wang","year":"2006","journal-title":"Physiology. (Bethesda)"},{"issue":"52","key":"10.1016\/j.neo.2026.101350_bib0043","doi-asserted-by":"crossref","first-page":"15790","DOI":"10.1073\/pnas.1521919112","article-title":"mTOR inhibition activates overall protein degradation by the ubiquitin proteasome system as well as by autophagy","volume":"112","author":"Zhao","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U S. A"},{"key":"10.1016\/j.neo.2026.101350_bib0044","article-title":"Research progress of HIF-1a on immunotherapy outcomes in immune vascular microenvironment","volume":"16","author":"Shi","year":"2025","journal-title":"Front. Immunol."},{"issue":"34","key":"10.1016\/j.neo.2026.101350_bib0045","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1038\/s41388-018-0303-3","article-title":"Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations","volume":"37","author":"Zerdes","year":"2018","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.neo.2026.101350_bib0046","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13045-020-01027-5","article-title":"Regulation of PD-L1 expression in the tumor microenvironment","volume":"14","author":"Yi","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"2","key":"10.1016\/j.neo.2026.101350_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellin.2024.100146","article-title":"PD-1-mediated inhibition of T cell activation: mechanisms and strategies for cancer combination immunotherapy","volume":"3","author":"Liu","year":"2024","journal-title":"Cell Insight"},{"issue":"Suppl 1","key":"10.1016\/j.neo.2026.101350_bib0048","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/2047-1440-2-S1-S2","article-title":"The influence of mTOR inhibitors on immunity and the relationship to post-transplant malignancy","volume":"2","author":"Geissler","year":"2013","journal-title":"TransPlant Res."},{"issue":"6","key":"10.1016\/j.neo.2026.101350_bib0049","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.3390\/cancers13061359","article-title":"Combining mTOR inhibitors and T cell-based immunotherapies in cancer treatment","volume":"13","author":"El Hage","year":"2021","journal-title":"Cancers. (Basel)"},{"issue":"1","key":"10.1016\/j.neo.2026.101350_bib0050","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/imr.12845","article-title":"mTOR signaling at the crossroads of environmental signals and T-cell fate decisions","volume":"295","author":"Huang","year":"2020","journal-title":"Immunol. Rev."},{"issue":"7251","key":"10.1016\/j.neo.2026.101350_bib0051","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/nature08155","article-title":"mTOR regulates memory CD8 T-cell differentiation","volume":"460","author":"Araki","year":"2009","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.neo.2026.101350_bib0052","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001955","article-title":"Targeting resistance to radiation-immunotherapy in cold HNSCCs by modulating the treg-dendritic cell axis","volume":"9","author":"Knitz","year":"2021","journal-title":"J. ImmunOther Cancer"},{"key":"10.1016\/j.neo.2026.101350_bib0053","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41417-021-00303-x","article-title":"Key chemokines direct migration of immune cells in solid tumors","volume":"29","author":"Kohli","year":"2022","journal-title":"Cancer Gene Therapy"},{"issue":"12","key":"10.1016\/j.neo.2026.101350_bib0054","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1111\/j.1600-6143.2009.02832.x","article-title":"The multifunctional role of mTOR in innate immunity: implications for transplant immunity","volume":"9","author":"S\u00e4emann","year":"2009","journal-title":"Am. J. TransPlant"},{"issue":"7","key":"10.1016\/j.neo.2026.101350_bib0055","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.4049\/jimmunol.1403134","article-title":"Tumor-infiltrating dendritic cells in cancer pathogenesis","volume":"194","author":"Tran Janco","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.neo.2026.101350_bib0056","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116930","article-title":"Macrophage polarization in the tumor microenvironment: emerging roles and therapeutic potentials","volume":"177","author":"Zhang","year":"2024","journal-title":"Biomed. PharmacOther"},{"issue":"4","key":"10.1016\/j.neo.2026.101350_bib0057","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3892\/ol.2022.13489","article-title":"Immunosuppressive effects of vascular endothelial growth factor","volume":"24","author":"Ribatti","year":"2022","journal-title":"Oncol. Lett."},{"issue":"20","key":"10.1016\/j.neo.2026.101350_bib0058","doi-asserted-by":"crossref","first-page":"11995","DOI":"10.1074\/jbc.273.20.11995","article-title":"p53 inhibits hypoxia-inducible factor-stimulated transcription","volume":"273","author":"Blagosklonny","year":"1998","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.neo.2026.101350_bib0059","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/imm.12036","article-title":"The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells","volume":"138","author":"Lindau","year":"2013","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.neo.2026.101350_bib0060","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1186\/s12935-025-03980-y","article-title":"The role of NK cells in regulating tumorimmunity: current state, challenges and future strategies","volume":"25","author":"Zhu","year":"2025","journal-title":"Cancer Cell Int."},{"issue":"9","key":"10.1016\/j.neo.2026.101350_bib0061","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.4049\/jimmunol.1401558","article-title":"mTORC1-dependent metabolic reprogramming is a prerequisite for NK cell effector function","volume":"193","author":"Donnelly","year":"2014","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.neo.2026.101350_bib0062","doi-asserted-by":"crossref","first-page":"iv350","DOI":"10.1093\/annonc\/mdu340.34","article-title":"Pd1 and Pdl1 in hpv + and hpv -\/Tp53 mutated head and neck squamous cell carcinomas","volume":"25","author":"Feldman","year":"2014","journal-title":"Ann. Oncol."},{"issue":"19","key":"10.1016\/j.neo.2026.101350_bib0063","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.21037\/atm-20-1846","article-title":"TP53 mutation and tumoral PD-L1 expression are associated with depth of invasion in desmoplastic melanomas","volume":"8","author":"Alos","year":"2020","journal-title":"Ann. Transl. Med."},{"issue":"12","key":"10.1016\/j.neo.2026.101350_bib0064","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1158\/1078-0432.CCR-16-2554","article-title":"Potential predictive value of TP53 and KRAS mutation status for response to PD-1 blockade immunotherapy in lung adenocarcinoma","volume":"23","author":"Dong","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.neo.2026.101350_bib0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2020.100847","article-title":"Searching for the real function of mTOR signaling in the regulation of PD-L1 expression","volume":"13","author":"Sun","year":"2020","journal-title":"Transl. Oncol."},{"issue":"7","key":"10.1016\/j.neo.2026.101350_bib0066","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112764","article-title":"Enhanced bypass of PD-L1 translation reduces the therapeutic response to mTOR kinase inhibitors","volume":"42","author":"Cao","year":"2023","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.neo.2026.101350_bib0067","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1158\/1541-7786.MCR-15-0159","article-title":"p53 Deletion or hotspot mutations enhance mTORC1 activity by altering lysosomal dynamics of TSC2 and Rheb","volume":"14","author":"Agarwal","year":"2016","journal-title":"Mol. Cancer Res."},{"issue":"2","key":"10.1016\/j.neo.2026.101350_bib0068","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/0008-5472.CAN-14-3362","article-title":"Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung cancer","volume":"76","author":"Lastwika","year":"2016","journal-title":"Cancer Res."},{"issue":"29","key":"10.1016\/j.neo.2026.101350_bib0069","doi-asserted-by":"crossref","first-page":"11988","DOI":"10.1073\/pnas.1310230110","article-title":"Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers","volume":"110","author":"Pourdehnad","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.neo.2026.101350_bib0070","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1084\/jem.20131916","article-title":"PD-L1 is a novel direct target of HIF-1\u03b1, and its blockade under hypoxia enhanced MDSC-mediated T cell activation","volume":"211","author":"Noman","year":"2014","journal-title":"J. Exp. Med."},{"issue":"9","key":"10.1016\/j.neo.2026.101350_bib0071","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.4049\/jimmunol.1901213","article-title":"Metformin enhances the antitumor activity of CD8+ T lymphocytes via the AMPK-miR-107-eomes-PD-1 pathway","volume":"204","author":"Zhang","year":"2020","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.neo.2026.101350_bib0072","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.immuni.2016.07.008","article-title":"Bioenergetic insufficiencies due to metabolic alterations regulated by the inhibitory receptor PD-1 are an early driver of CD8(+) T cell exhaustion","volume":"45","author":"Bengsch","year":"2016","journal-title":"Immunity"},{"issue":"60","key":"10.1016\/j.neo.2026.101350_bib0073","doi-asserted-by":"crossref","first-page":"eabg0791","DOI":"10.1126\/sciimmunol.abg0791","article-title":"Activation of mTORC1 at late endosomes misdirects T cell fate decision in older individuals","volume":"6","author":"Jin","year":"2021","journal-title":"Sci. Immunol."},{"issue":"2","key":"10.1016\/j.neo.2026.101350_bib0074","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/cei.13407","article-title":"TIGIT as an emerging immune checkpoint","volume":"200","author":"Harjunp\u00e4\u00e4","year":"2020","journal-title":"Clin. Exp. Immunol."},{"issue":"2","key":"10.1016\/j.neo.2026.101350_bib0075","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/lio2.370","article-title":"mTOR inhibitor use in head and neck squamous cell carcinoma: a meta-analysis on survival, tumor response, and toxicity","volume":"5","author":"Patel","year":"2020","journal-title":"Laryngoscope Investig. Otolaryngol."},{"issue":"8","key":"10.1016\/j.neo.2026.101350_bib0076","article-title":"Combination of dual mTORC1\/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity","volume":"7","author":"Langdon","year":"2018","journal-title":"Oncoimmunology"}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558626000813?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558626000813?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:38:33Z","timestamp":1788262713000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558626000813"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":76,"alternative-id":["S1476558626000813"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2026.101350","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"mTOR inhibition augments antitumor immune effector response by reprogramming the TP53-mutant, immune-cold HNSCC tumor microenvironment","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2026.101350","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101350"}}